-+ 0.00%
-+ 0.00%
-+ 0.00%

IDEAYA targets year-end 2026 start for Phase 3 IDE849 trial in extensive-stage small cell lung cancer

PUBT·08/31/2026 10:01:36
Listen to the news
IDEAYA targets year-end 2026 start for Phase 3 IDE849 trial in extensive-stage small cell lung cancer
  • IDEAYA Biosciences plans to start a randomized Phase 3 registrational trial of IDE849 in extensive-stage small cell lung cancer by year-end 2026.
  • The design targets a single study that could support accelerated approval based on tumor response and full approval based on survival.
  • The trial aims to enroll about 400 patients previously treated with tarlatamab, comparing IDE849 with investigator’s choice chemotherapy.
  • Dose selection is still underway in an ongoing Phase 1 program to set the recommended Phase 3 dose.
  • Additional clinical updates are scheduled for ESMO 2026, with further results expected from an IDEAYA-sponsored study in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608310600PR_NEWS_USPR_____SF35790) on August 31, 2026, and is solely responsible for the information contained therein.